Publications

Affichage de 21 à 30 sur 5364


  • Article dans une revue

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Cyrille Touzeau, Amrita Krishnan, Philippe Moreau, Aurore Perrot, Saad Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay Nooka, Lionel Karlin, Xavier Leleu, Xavier Leleu, Nizar Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred Garfall

Abstract Teclistamab is a B-cell maturation antigen (BCMA)–directed bispecific antibody approved for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). In the phase 1/2 MajesTEC-1 study, a cohort of patients who had prior BCMA-targeted therapy (…

Blood, 2024, 144 (23), pp.2375-2388. ⟨10.1182/blood.2023023616⟩. ⟨hal-04922674⟩

Lu
Ma
Me
Je
Ve
Sa
Di
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
5
6
Effacer
Lu
Ma
Me
Je
Ve
Sa
Di
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
5
6
Effacer